SALT LAKE CITY, June 16, 2026 /PRNewswire/ -- Clinical laboratories, including ARUP Laboratories, are reviewing newly introduced federal legislation to modernize oversight of laboratory-developed ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cellworks Group, Inc., a leader in Personalized Therapy Decision Support and Precision Drug Development, today announced that its computational laboratory ...

CLIA certification for the Allarity Therapeutics Medical Laboratory is a critical strategic initiative to streamline the development of Allarity’s lead agent, stenoparib Positions Allarity ...

NATICK, Mass.--(BUSINESS WIRE)--Pillar Biosciences, an innovative, next-generation sequencing (NGS) solutions, in-vitro diagnostics (IVD) company, today announced that its NGS laboratory, located in ...

The Company plans to expand in the medical diagnostic testing space via mobile modular units. SG Blocks will own and operate these units, providing its own end-to-end solution including both staffing ...

“We have been working with Todos Medical for several months and believe they’ve put together the most comprehensive set of testing solutions that our organization needs to effectively execute our ...

Almac’s Diagnostics business unit has announced the opening of its CLIA registered laboratory. The opening of the Almac CLIA Laboratory supports the company’s ongoing Biomarker Discovery and ...

New regulations under the Clinical Laboratory Improvement Amendments (CLIA) introduced updated proficiency testing (PT) and PT referral rules that are now in effect. Although the regulations became ...

Firm will configure MutliGen tests on transrenal platform. Molecular diagnostics firm TrovaGene is to acquire MultiGen Diagnostics’ CLIA-certified laboratory in return for 750,000 shares of TrovaGene ...

The undertaking of research in human participants often includes development of clinical laboratory test results associated with an individual research participant. Depending in part on the specified ...

TARPON SPRINGS, Fla., July 7, 2026 – Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib ...